Defective Medicinal Products and Recall Management Guidance
The main concerns with regard to possible defects of medicinal products and the substances used in their manufacture or packaging.
The main concerns with regard to possible defects of medicinal products and the substances used in their manufacture or packaging.
Medicinal products seized within the week running from the 23rd-30th June, the Medicines and Healthcare products Regulatory Agency (MHRA) seized 285,000 medicines and medical devices which were valued at almost £1,000,000.
Import Licensed Human Medicine – Prior to importation of a licensed medicine applications for the relevant Licence(s) must be completed and submitted which may include one or more of the following:
An Introduced Product is an unlicensed medicine which can be imported from a country other than an approved country for import to be exported to a country other than an approved country for import, or if imported from a non-EEA country into Northern Ireland for export back to a country outside the EEA.
For the distribution of medicines and healthcare products, a licence, authorisation or registration is required depending on the type of activity.
There is a new MHRA Green Guide Update 2022 updated edition of the Rules and Guidance for Pharmaceutical Distributors called the MHRA Green Guide.